title: No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.
abstract: OBJECTIVE
  The aim of the present study was to evaluate the possible effects of Q10 and selenium supplementation on statin-induced myopathy (SIM), both for subjective symptoms and muscle function.
  
  
  METHODS
  Patients (N = 43) who had experienced previous or ongoing SIM on atorvastatin therapy were recruited. Following a 6-week washout period during which no statins were administered, the patients were re-challenged with 10 mg of atorvastatin. Patients (N = 41) who experienced SIM continued the atorvastatin treatment and were in addition randomized to receive 12 weeks supplement of 400 mg Q10 and 200 μg selenium per day or a matching double placebo. SIM was assessed using 3 validated symptom questionnaires, and a muscle function test was performed at the beginning and at the end of the study.
  
  
  RESULTS
  The patients receiving the active supplement experienced significant increases in their serum Q10 and selenium concentrations compared with the group receiving placebo. No statistically significant differences in symptom questionnaire scores or muscle function tests were revealed between the groups.
  
  
  CONCLUSIONS
  Despite substantial increases in the serum Q10 and selenium levels following the oral supplementation, this study revealed no significant effects on SIM compared with the placebo.
authors.affiliation: Department of Internal Medicine, Møre and Romsdal Health Trust, Ålesund Hospital, Ålesund, Norway. martinbogsrud@gmail.com
authors.forename: Martin Prøven
authors.initials: MP
authors.lastname: Bogsrud
authors.forename: Gisle
authors.initials: G
authors.lastname: Langslet
authors.forename: Leiv
authors.initials: L
authors.lastname: Ose
authors.forename: Kjell-Erik
authors.initials: KE
authors.lastname: Arnesen
authors.forename: Milada Cvancarova
authors.initials: MC
authors.lastname: Sm Stuen
authors.forename: Ulrik Fredrik
authors.initials: UF
authors.lastname: Malt
authors.forename: Berit
authors.initials: B
authors.lastname: Woldseth
authors.forename: Kjetil
authors.initials: K
authors.lastname: Retterstøl
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage*; D000069059:Atorvastatin; D019587:Dietary Supplements; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D012643:Selenium / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014815:Vitamins / Q000008:administration & dosage*
chemical_list: D000975:Antioxidants; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014815:Vitamins; D014451:Ubiquinone; D000069059:Atorvastatin; C024989:coenzyme Q10; D012643:Selenium